# Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer

> **NCT03073785** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Nebraska** · enrollment: 46 (actual)

## Conditions studied

- Pancreatic Adenocarcinoma
- Recurrent Pancreatic Carcinoma
- Stage I Pancreatic Cancer AJCC v6 and v7
- Stage IA Pancreatic Cancer AJCC v6 and v7
- Stage IB Pancreatic Cancer AJCC v6 and v7
- Stage II Pancreatic Cancer AJCC v6 and v7
- Stage IIA Pancreatic Cancer AJCC v6 and v7
- Stage IIB Pancreatic Cancer AJCC v6 and v7
- Stage III Pancreatic Cancer AJCC v6 and v7
- Stage IV Pancreatic Cancer AJCC v6 and v7

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Fluorouracil
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **RADIATION:** Stereotactic Body Radiation Therapy
- **DRUG:** Zoledronic Acid

## Key facts

- **NCT ID:** NCT03073785
- **Lead sponsor:** University of Nebraska
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-09-16
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2025-05-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03073785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03073785, "Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT03073785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*